Leveraging Blood-Based Biomarkers Beyond Oncology to Accelerate Clinical Trial Readouts

• Applying assay development and validation practice built in oncology to blood-based biomarkers in neurodegeneration and other non-oncology indications
• Reducing reliance on invasive and costly procedures such as imaging and tissue or CSF sampling, lowering screening cost and widening trial recruitment
• Adapting sampling and operational models to diseases that progress over years rather than weeks

Speakers:

Joel Mathews

Director - Biomarker Strategy, Organization Building, Neuroscience & Immunology

Ionis Pharmaceuticals, Inc.